Search research articles
Contact Us
Filters
Showing results (181-190 of 349) with videos related to
Page
of 35
Sort By:
Circulation
|
June 28, 2022
Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
Gerasimos Filippatos, Javed Butler, Dimitrios Farmakis, et al.
Journal of the American College of Cardiology
|
July 3, 2007
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank
G Michael Felker, Larry A Allen, Stuart J Pocock, et al.
JACC. Cardiovascular Interventions
|
November 21, 2015
Diagnostic and Prognostic Implications of Coronary Flow Capacity: A Comprehensive Cross-Modality Physiological Concept in Ischemic Heart Disease
Tim P van de Hoef, Mauro Echavarría-Pinto, Martijn A van Lavieren, et al.
Diabetes Care
|
May 13, 2011
Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study
Michael R MacDonald, Mark C Petrie, Philip D Home, et al.
JACC. Heart Failure
|
October 11, 2020
Estimating the Lifetime Benefits of Treatments for Heart Failure
João Pedro Ferreira, Kieran F Docherty, Susan Stienen, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
February 4, 2021
Long-Term Antithrombotic Therapy and Clinical Outcomes in Patients with Acute Coronary Syndrome and Renal Impairment: Insights from EPICOR and EPICOR Asia
Yong Huo, Frans Van de Werf, Yaling Han, et al.
European Heart Journal
|
September 30, 2008
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme
Stuart J Pocock, John J V McMurray, Joanna Dobson, et al.
European Journal of Heart Failure
|
September 10, 2022
Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial
Michael Böhm, Javed Butler, Felix Mahfoud, et al.
European Heart Journal
|
August 23, 2021
Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial
Stuart J Pocock, João Pedro Ferreira, John Gregson, et al.
The American Journal of Cardiology
|
November 13, 2016
Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes
Mikkel M Schoos, Roxana Mehran, George D Dangas, et al.
Page
of 35
Search research articles
Search
Showing results (181-190 of 349) with videos related to
Sort By:
Page
of 35
Circulation
|
June 28, 2022
Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
Gerasimos Filippatos, Javed Butler, Dimitrios Farmakis, et al.
Journal of the American College of Cardiology
|
July 3, 2007
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank
G Michael Felker, Larry A Allen, Stuart J Pocock, et al.
JACC. Cardiovascular Interventions
|
November 21, 2015
Diagnostic and Prognostic Implications of Coronary Flow Capacity: A Comprehensive Cross-Modality Physiological Concept in Ischemic Heart Disease
Tim P van de Hoef, Mauro Echavarría-Pinto, Martijn A van Lavieren, et al.
Diabetes Care
|
May 13, 2011
Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study
Michael R MacDonald, Mark C Petrie, Philip D Home, et al.
JACC. Heart Failure
|
October 11, 2020
Estimating the Lifetime Benefits of Treatments for Heart Failure
João Pedro Ferreira, Kieran F Docherty, Susan Stienen, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
February 4, 2021
Long-Term Antithrombotic Therapy and Clinical Outcomes in Patients with Acute Coronary Syndrome and Renal Impairment: Insights from EPICOR and EPICOR Asia
Yong Huo, Frans Van de Werf, Yaling Han, et al.
European Heart Journal
|
September 30, 2008
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme
Stuart J Pocock, John J V McMurray, Joanna Dobson, et al.
European Journal of Heart Failure
|
September 10, 2022
Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial
Michael Böhm, Javed Butler, Felix Mahfoud, et al.
European Heart Journal
|
August 23, 2021
Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial
Stuart J Pocock, João Pedro Ferreira, John Gregson, et al.
The American Journal of Cardiology
|
November 13, 2016
Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes
Mikkel M Schoos, Roxana Mehran, George D Dangas, et al.
Page
of 35